KF-0210, developed independently by Keythera Biopharmaceuticals, is a small molecular drug designed to combat tumors by regulating the tumor immune microenvironment and enhancing the body's anti-tumor immune response, thereby inhibiting tumor growth and metastasis. KF-0210 had previously received approval for its first human clinical trial in Australia in December 2020 (NCT04713891), and the first patient was administered the drug on March 9, 2021.

The ongoing clinical development in China will further evaluate the safety, tolerability, pharmacokinetic characteristics , and preliminary clinical efficacy of KF-0210 in Chinese advanced solid tumor patients. Despite the active search and development of anti-tumor drugs by numerous companies, there remains an unmet medical need for for advanced solid tumors. Dr. Yongqi Deng, Chairman and CEO of Keythera Biopharmaceuticals, expressed the hope that the successful development of KF-0210 would provide more solutions for clinical anti-tumor therapy, benefit more cancer patients, improve their quality of life, and reduce the burden on families and society.

Back to List